[Sodium benzoate in portal-systemic-encephalopathy-induced blood ammonia normalization and clinical improvement. Interim report of a double-blind multicenter trial].
To investigate the therapeutic efficacy of sodium benzoate (SB) in a cirrotic population with chronic portal systemic encepalopathy (PSE), we performed a double blind, randomised, multicentric, clinical trial, comparing SB versus a standard therapy of lactitol (LA). To perform the study blind, syrups containing the two drugs were prepared. To date 27 patients have been studied. Of these, 12 received SB (5.6 g/day) and 15 received LA (29 g/day). Standard PSE parameters were assessed and hippurate urinary excretion was measured before and after the trial. For the SB group, basal and final PSE index were 0.39 +/- 0.16 and 0.17 +/- 0.1 respectively (p < 0.001). The Group on LA had a PSE index of 0.40 + 0.1 and 0.23 +/- 0.18 (basal and final respectively) (p < 0.001). The final hippurate excretion for SB group was 2498.9 mg/24 h. The hippurate excretion for the LA group suffer no changes (traces). No serious side effects were observed with either therapy. We suggested that SB is a safe, efficacious and comfortable alternate treatment for PSE.
Uribe
M
M
Departamento de Gastroenterología Instituto Nacional de la Nutrición "Salvador Zubirán", Vasco de Quiroga No. 15, Tlalpan, México 14000, DF.
Bosques
F
F
Marín
E
E
Cervera
E
E
Gil
S
S
Luis Poo
J
J
Garcia Compeán
D
D
Santoyo
R
R
Huerta
E
E
García-Ramos
G
G
Cadena
M
M
Merikansky
A
A
Robledo
J
J
Cortés
M
M
Guevara
A
A
López
N
N
Aguilar
A
A
Alejandra Ochoa
E
E
D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006501:Hepatic Encephalopathy / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism; D006626:Hippurates / Q000652:urine; D006801:Humans; D022124:Hyperammonemia / Q000188:drug therapy* / Q000209:etiology / Q000652:urine; D008103:Liver Cirrhosis / Q000150:complications; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D012720:Severity of Illness Index; D020160:Sodium Benzoate / Q000627:therapeutic use*; D016896:Treatment Outcome
D006626:Hippurates; D020160:Sodium Benzoate